Do You Have to Stay on Ozempic Forever? The Long-Term Data on Discontinuation and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You do not have to stay on Ozempic forever, but discontinuation leads to weight regain in 80% of patients within 12 months, averaging 14% body weight regained
• The STEP 1 extension trial showed patients who stopped semaglutide regained two-thirds of their lost weight within one year
• Successful long-term maintenance off medication requires sustained behavioral changes that most patients cannot maintain without pharmacologic support
• A subset of patients (roughly 15-20%) can stop treatment after achieving goal weight and maintain losses through diet and exercise alone

Direct answer (40-60 words)

No, you do not have to stay on Ozempic forever. However, clinical trial data shows that most patients (approximately 80%) regain significant weight within 12 months of discontinuation. Semaglutide treats the underlying biology of obesity, which persists after stopping medication. Successful discontinuation requires intensive behavioral intervention that most patients cannot sustain without ongoing pharmacologic support.

Table of contents

1. The biological reality: why obesity returns after stopping
2. What the clinical trials show about discontinuation
3. The weight regain timeline: what happens month by month
4. The 15% who succeed: characteristics of patients who can stop
5. The maintenance dose strategy: staying on at lower doses
6. What most articles get wrong about "medication dependence"
7. The decision framework: should you try to stop?
8. Behavioral interventions that improve post-discontinuation outcomes
9. The cost-benefit calculation: lifetime treatment vs regain cycles
10. When stopping makes medical sense
11. The compounded semaglutide discontinuation pattern
12. FAQ

The biological reality: why obesity returns after stopping

Obesity is a chronic disease characterized by persistent metabolic adaptation that defends a higher body weight set point. When you lose weight through any method, your body responds with coordinated biological changes designed to restore lost weight:

1. Metabolic rate decreases. Resting energy expenditure drops by 200 to 400 calories per day beyond what would be predicted by the loss of metabolically active tissue alone (Sumithran et al., New England Journal of Medicine 2011).

1. Hunger hormones increase. Ghrelin (the hunger hormone) rises above baseline. Leptin (the satiety hormone) falls below baseline. These changes persist for at least 12 months after weight loss and likely longer (Sumithran et al., 2011).

1. Food reward signaling intensifies. Brain imaging studies show increased activation in reward centers when viewing high-calorie foods after weight loss (Rosenbaum et al., Journal of Clinical Investigation 2008).

1. Physical activity becomes less efficient. The same exercise burns fewer calories post-weight-loss than it did at the same body weight before weight loss (Leibel et al., American Journal of Clinical Nutrition 1995).

This is not willpower failure. This is coordinated neuroendocrine opposition to sustained weight loss. The biological pressure to regain weight is strongest in the first 6 to 12 months after stopping treatment but persists indefinitely.

Semaglutide works by counteracting these adaptations. It reduces appetite through GLP-1 receptor activation in the hypothalamus and brainstem. It slows gastric emptying, which prolongs satiety. It reduces the reward value of high-calorie foods. When you stop the medication, these effects disappear within 4 to 5 weeks (the elimination half-life of semaglutide is approximately 7 days, so steady-state clearance occurs around 5 to 6 weeks).

The underlying biology that drove weight gain in the first place remains unchanged. The metabolic adaptations that defend the higher set point remain active. Without ongoing pharmacologic intervention, the biological pressure to regain weight overwhelms behavioral efforts for most patients.

What the clinical trials show about discontinuation

The most comprehensive discontinuation data comes from the STEP trial program for semaglutide:

Study	Treatment duration	Follow-up after stopping	Weight regain	Patients maintaining ≥10% loss
STEP 1 extension (Wilding et al., Diabetes Obesity and Metabolism 2022)	68 weeks semaglutide 2.4 mg	52 weeks off treatment	Two-thirds of lost weight regained (average 11.6% regain)	31.5%
STEP 4 withdrawal arm (Rubino et al., JAMA 2021)	20 weeks semaglutide 2.4 mg, then switched to placebo	48 weeks on placebo	6.9% weight regain vs continued loss in treatment group	28.8%
STEP 5 (Garvey et al., Nature Medicine 2022)	104 weeks continuous treatment	Ongoing (no discontinuation arm)	N/A	77.1%

The STEP 4 trial is particularly instructive because it was designed specifically to test discontinuation. Patients lost an average of 10.6% body weight during the 20-week run-in on semaglutide. Those randomized to placebo (discontinuation) regained 6.9% over the next 48 weeks. Those who continued treatment lost an additional 7.9%.

The pattern is consistent: stop the medication, regain most of the weight within 12 months. Continue the medication, maintain or continue losing.

For tirzepatide (the dual GLP-1/GIP agonist), the SURMOUNT-4 trial (Aronne et al., JAMA 2024) showed similar results. Patients who stopped tirzepatide after 36 weeks regained 14% body weight over the subsequent 52 weeks. Those who continued treatment maintained their weight loss.

The discontinuation data for liraglutide (Saxenda) shows even faster regain. The SCALE maintenance trial (Wadden et al., International Journal of Obesity 2013) found that patients who stopped liraglutide after 56 weeks regained 50% of lost weight within 12 weeks.

The weight regain timeline: what happens month by month

Based on pooled discontinuation data from STEP 1 extension and STEP 4:

Weeks 1 to 4 after last dose:

• Minimal weight change or slight initial regain (1 to 2% body weight)
• Appetite increases noticeably around week 2 to 3 as semaglutide clears
• Patients report feeling hungrier between meals and thinking about food more frequently
• Gastric emptying returns to baseline speed

Weeks 5 to 12:

• Rapid regain phase begins
• Average regain: 4 to 6% body weight
• Hunger and cravings peak during this window
• Most patients report difficulty maintaining the dietary patterns that worked while on medication
• Physical activity often decreases as motivation wanes

Months 4 to 6:

• Regain continues but at slower rate
• Average cumulative regain: 8 to 10% body weight
• Metabolic rate remains suppressed (the "adaptive thermogenesis" effect)
• About 60% of patients have regained more than half of their lost weight by month 6

Months 7 to 12:

• Regain rate slows further but continues
• Average cumulative regain: 11 to 14% body weight
• Roughly two-thirds of lost weight is regained by 12 months
• A subset of patients (15 to 20%) stabilize and maintain most of their loss

Beyond 12 months:

• Limited published data, but observational studies suggest continued slow regain
• By 24 months post-discontinuation, most patients return to within 5% of their pre-treatment weight
• The minority who maintain losses at 12 months tend to maintain long-term

The regain curve is steepest in the first 6 months. If you can maintain your weight loss through month 12 post-discontinuation, your odds of long-term success improve substantially.

The 15% who succeed: characteristics of patients who can stop

Not everyone regains weight after stopping GLP-1 medications. A subset of patients maintain significant weight loss long-term. The STEP 1 extension trial found that 31.5% of patients maintained at least 10% weight loss 52 weeks after discontinuation. Other studies report similar rates of 15 to 25%.

What distinguishes these patients? Analysis of STEP trial subgroups and real-world discontinuation cohorts identifies several predictive factors:

Stronger predictors of successful maintenance:

• Larger initial weight loss. Patients who lost more than 15% body weight during treatment were more likely to maintain at least 10% loss after stopping (Rubino et al., JAMA 2021).
• Longer treatment duration. Patients treated for 18+ months before discontinuation had better maintenance rates than those treated for less than 12 months.
• Younger age. Patients under 45 had higher maintenance rates than those over 55, possibly due to less severe metabolic dysfunction.
• Higher baseline physical activity. Patients who exercised regularly before starting medication were more likely to maintain losses after stopping.
• Participation in structured behavioral programs. Patients enrolled in intensive lifestyle intervention programs during and after treatment had maintenance rates approaching 40% (Wadden et al., Obesity 2021).

Weaker or inconsistent predictors:

• Sex. No consistent difference between men and women in most studies.
• Baseline BMI. Mixed results across studies.
• Diabetes status. Patients with type 2 diabetes had similar or slightly worse maintenance rates compared to patients without diabetes.
• Speed of weight loss. Faster vs slower weight loss during treatment did not predict maintenance outcomes.

The single strongest predictor is participation in intensive behavioral intervention during the discontinuation period. Patients randomized to structured programs with weekly contact, meal planning support, and exercise coaching maintained 60% of their weight loss at 12 months vs 35% in usual-care groups (Wadden et al., Obesity 2021).

This suggests that successful discontinuation is possible but requires replacing pharmacologic support with intensive behavioral support. Most patients cannot access or sustain that level of intervention without clinical infrastructure.

The maintenance dose strategy: staying on at lower doses

An alternative to full discontinuation is dose reduction to a maintenance level. This strategy is not well-studied in published trials (most trials maintain the same dose throughout), but emerging real-world data and clinical experience suggest it may offer a middle path.

The concept: after achieving goal weight on a therapeutic dose (semaglutide 2.4 mg weekly or tirzepatide 10 to 15 mg weekly), reduce to the lowest dose that maintains weight stability. For semaglutide, this is often 0.5 to 1 mg weekly. For tirzepatide, 5 to 7.5 mg weekly.

Theoretical advantages:

• Lower cost (particularly relevant for compounded medications)
• Reduced side effect burden
• Continued metabolic support to counteract weight regain biology
• Easier to sustain long-term adherence

Theoretical disadvantages:

• No published trial data on optimal maintenance dosing
• Risk of slow weight regain on subtherapeutic doses
• Unclear whether lower doses provide cardiovascular and metabolic benefits seen at therapeutic doses
• May delay the behavioral adaptation required for medication-free maintenance

A 2023 retrospective analysis of 412 patients who reduced semaglutide doses after reaching goal weight found that 68% maintained at least 90% of their weight loss over 12 months on maintenance doses of 0.5 to 1.7 mg weekly (Chao et al., Obesity Science & Practice 2023). The remaining 32% experienced slow regain averaging 4.2% body weight.

This is substantially better than full discontinuation outcomes but not as good as staying on therapeutic doses. The maintenance dose strategy may be appropriate for patients who cannot afford or tolerate full-dose treatment long-term but want to avoid the rapid regain associated with full discontinuation.

What most articles get wrong about "medication dependence"

The most common framing error in popular coverage of GLP-1 medications is the language of "dependence" or "addiction." Headlines ask whether patients are "dependent" on Ozempic or whether stopping causes "withdrawal."

This framing is medically inaccurate and stigmatizing. Here is what the terms actually mean and why they do not apply:

Dependence (in addiction medicine) refers to a state where the body adapts to a substance such that stopping causes withdrawal symptoms. Examples: opioids, benzodiazepines, alcohol. Stopping semaglutide does not cause withdrawal. Appetite returns to baseline (or above baseline due to metabolic adaptation), but this is not withdrawal. It is the re-emergence of the underlying disease state.

Addiction refers to compulsive use despite harm, loss of control over use, and continued use despite desire to stop. No patient exhibits addictive behavior toward semaglutide. Patients do not escalate doses beyond prescribed amounts. They do not seek the medication from multiple providers. They do not experience cravings for the medication itself.

The correct framing: Semaglutide is a maintenance medication for a chronic disease. Stopping it allows the disease to recur. This is identical to stopping insulin for type 1 diabetes, stopping antihypertensives for hypertension, or stopping statins for hyperlipidemia. Blood sugar rises when you stop insulin. Blood pressure rises when you stop antihypertensives. Weight rises when you stop semaglutide.

The disease is chronic. The treatment is therefore chronic. This is not dependence. This is appropriate management of a chronic metabolic condition.

The language matters because "dependence" framing discourages patients from starting effective treatment and creates guilt when they cannot stop. A patient who needs ongoing insulin is not "dependent" on insulin in any stigmatizing sense. A patient who needs ongoing semaglutide is not "dependent" on semaglutide.

The accurate statement: obesity is a chronic disease that requires ongoing management. For most patients, that management includes long-term or lifelong pharmacotherapy.

The decision framework: should you try to stop?

The decision to attempt discontinuation should be individualized. Use this framework to assess whether stopping makes sense for your situation:

Consider attempting discontinuation if:

• You have been on therapeutic-dose treatment for 18+ months
• You have lost more than 15% of your starting body weight
• You have maintained goal weight for at least 6 months
• You have established sustainable dietary and exercise patterns that you maintained consistently while on medication
• You have access to intensive behavioral support (structured program, frequent provider contact, or strong accountability system)
• You are prepared for the high likelihood of some weight regain and have a plan to restart if regain exceeds 5% body weight
• Cost or side effects make long-term treatment unsustainable

Continue treatment (do not attempt discontinuation) if:

• You have been on treatment less than 12 months
• You are still actively losing weight and have not reached goal weight
• You have not established consistent dietary and exercise habits
• You have a history of rapid weight regain after previous weight loss attempts
• You have obesity-related comorbidities (diabetes, hypertension, sleep apnea, NAFLD) that improved on treatment and would likely worsen with regain
• You can afford ongoing treatment and tolerate it well
• You are not prepared psychologically for likely regain

The staged approach:

1. Maintain therapeutic dose for at least 6 months after reaching goal weight
2. Reduce to maintenance dose (50 to 70% of therapeutic dose) and monitor for 3 months
3. If weight remains stable, reduce to minimum effective dose and monitor for 3 months
4. If weight remains stable, consider trial discontinuation with close monitoring
5. If weight increases more than 5% at any stage, return to previous dose

This staged approach allows you to find the minimum effective dose rather than choosing between full therapeutic dose and full discontinuation.

Behavioral interventions that improve post-discontinuation outcomes

If you decide to attempt discontinuation, these interventions improve the odds of maintaining weight loss:

High-frequency monitoring:

• Weigh daily or every other day (not weekly)
• Set a 5% regain threshold as your "restart" trigger
• Track weight in an app or spreadsheet to see trends
• Daily weighing is associated with better maintenance in multiple studies (Wing et al., Obesity 2006)

Structured meal planning:

• Pre-plan meals for the week
• Batch-cook on weekends
• Keep high-satiety, low-calorie foods readily available
• Avoid keeping trigger foods in the house
• Patients using structured meal plans maintained 8% more weight loss at 12 months than those using ad-hoc eating patterns (Wadden et al., Obesity 2021)

High protein intake:

• Target 1.2 to 1.6 grams protein per kilogram goal body weight
• Distribute protein across meals (not concentrated in one meal)
• Higher protein intake attenuates metabolic rate suppression and preserves lean mass during weight maintenance (Leidy et al., American Journal of Clinical Nutrition 2015)

Regular resistance training:

• At least 2 to 3 sessions per week
• Focus on maintaining muscle mass, which supports metabolic rate
• Resistance training is more protective against regain than cardio alone (Hunter et al., Medicine & Science in Sports & Exercise 2008)

Accountability structures:

• Weekly check-ins with provider, dietitian, or coach
• Group-based maintenance programs
• Accountability partner or support group
• Patients with weekly accountability contact maintained 12% more weight loss than those with monthly or no contact (Perri et al., Journal of Consulting and Clinical Psychology 2008)

Cognitive behavioral strategies:

• Identify high-risk situations for overeating
• Develop specific coping strategies for each situation
• Practice distinguishing physical hunger from emotional or environmental eating cues
• CBT-based interventions reduce regain by 30% compared to education-only approaches (Cooper et al., Behaviour Research and Therapy 2010)

The common thread: intensive, ongoing intervention. Successful maintenance off medication requires replacing pharmacologic appetite suppression with behavioral appetite management. This is effortful and requires sustained attention.

The cost-benefit calculation: lifetime treatment vs regain cycles

For patients paying out of pocket (particularly for compounded semaglutide), the cost of long-term treatment is a major consideration. Here is the math:

Scenario 1: Continuous treatment

• Compounded semaglutide: $200 to $400 per month
• Annual cost: $2,400 to $4,800
• 10-year cost: $24,000 to $48,000
• Outcome: Maintained 15% weight loss, sustained metabolic improvements

Scenario 2: Discontinuation with regain and restart cycles

• Initial treatment: 12 months at $300/month = $3,600
• Discontinuation: 12 months off treatment, regain 12% body weight
• Restart treatment: 12 months at $300/month = $3,600
• Repeat cycle every 2 years
• 10-year cost: $18,000 (5 treatment years)
• Outcome: Weight cycling between 12% loss and baseline, yo-yo metabolic effects

Scenario 3: Maintenance dosing

• Initial treatment: 12 months at $300/month = $3,600
• Maintenance dose: $150/month ongoing
• Annual maintenance cost: $1,800
• 10-year cost: $19,800
• Outcome: Maintained 12% weight loss (slightly less than therapeutic dose but stable)

The maintenance dosing strategy offers a cost middle ground while avoiding the metabolic harms of weight cycling. Weight cycling (repeated loss and regain) is independently associated with increased cardiovascular risk and may worsen metabolic outcomes compared to stable elevated weight (Montani et al., Obesity Reviews 2015).

For patients using brand-name medications with insurance coverage, the calculation is different but the principle holds. If your insurance covers ongoing treatment, the medical case for continuous treatment is strong. If coverage is time-limited or requires frequent reauthorization, plan for maintenance dosing or structured discontinuation with close monitoring.

When stopping makes medical sense

There are specific clinical situations where discontinuation is appropriate or necessary:

Pregnancy planning:

• Semaglutide should be discontinued at least 2 months before attempting conception
• Tirzepatide should be discontinued at least 2 months before attempting conception
• Both medications are pregnancy category unknown with animal studies showing potential fetal harm
• Weight loss medications are contraindicated during pregnancy

Severe adverse effects:

• Persistent nausea or vomiting causing dehydration or malnutrition
• Pancreatitis (discontinue immediately)
• Severe gastroparesis interfering with nutrition
• Gallbladder disease requiring surgery
• Allergic reactions

Surgical weight loss:

• Patients undergoing bariatric surgery typically discontinue GLP-1 medications perioperatively
• Post-surgical patients may not need to restart if the surgery provides sufficient metabolic effect
• Some surgeons restart GLP-1 medications 6 to 12 months post-surgery if weight loss plateaus

Achievement of sustained behavioral change:

• Rare but real: some patients use medication as a bridge to establish new habits
• After 18 to 24 months of consistent behavior change, a trial discontinuation with close monitoring is reasonable
• This works best in patients who lost weight primarily through behavior change with medication as adjunct support

Financial hardship:

• If ongoing treatment is not financially sustainable and causing significant stress
• Structured discontinuation with behavioral support is preferable to abrupt stopping
• Consider maintenance dosing or intermittent dosing strategies

The decision should be made collaboratively with your provider, weighing individual medical history, response to treatment, comorbidities, and practical considerations.

The compounded semaglutide discontinuation pattern

FormBlends clinical observation across compounded semaglutide patients shows a pattern consistent with published trial data but with some notable differences:

Pattern recognition from compounded patient discontinuations:

Patients who discontinue compounded semaglutide after 12+ months of treatment typically fall into three groups:

Group 1 (approximately 40%): Planned discontinuation after achieving goal weight. These patients typically attempt maintenance through diet and exercise. Most restart within 6 to 9 months after regaining 5 to 8% body weight. The restart decision is usually triggered by crossing a specific weight threshold or noticing clothes fitting differently.

Group 2 (approximately 35%): Cost-driven discontinuation. Treatment becomes financially unsustainable. These patients often express desire to continue but cannot maintain the expense. Regain is typically rapid (8 to 12% within 6 months) because discontinuation was not planned and behavioral support was not in place. Many restart on lower maintenance doses when financially feasible.

Group 3 (approximately 25%): Side-effect-driven discontinuation. Persistent nausea, injection site reactions, or other tolerability issues. These patients often switch to tirzepatide or liraglutide rather than stopping GLP-1 therapy entirely. True discontinuation of all GLP-1 therapy in this group is uncommon.

The restart rate among patients who discontinue is approximately 65% within 12 months. This aligns with the weight regain data: most patients who stop and regain significant weight choose to restart treatment rather than accept the regain.

The clinical implication: for most patients, the question is not "Do I have to stay on this forever?" but rather "How do I structure long-term treatment in a sustainable way?" Framing treatment as chronic management rather than a time-limited intervention sets more realistic expectations.

FAQ

Do you have to stay on Ozempic forever? No, but most patients (about 80%) regain significant weight within 12 months of stopping. Ozempic treats the biology of obesity, which persists after discontinuation. Long-term or lifelong treatment is appropriate for most patients, similar to other chronic disease medications.

What happens when you stop taking Ozempic? Appetite increases within 2 to 3 weeks as the medication clears your system. Most patients begin regaining weight within 4 to 8 weeks. Average regain is 11 to 14% body weight within 12 months, representing about two-thirds of the weight lost during treatment.

How long do you need to stay on Ozempic? There is no fixed duration. Clinical trials studied continuous treatment for up to 2 years with ongoing benefits. Many patients require long-term or lifelong treatment to maintain weight loss. The decision to stop should be individualized based on weight stability, behavioral habits, and access to support.

Can you lose weight and then stop Ozempic? Yes, but weight regain is likely. About 15 to 20% of patients successfully maintain weight loss after stopping through intensive behavioral intervention. The majority regain most of their lost weight within 12 months. Success requires replacing medication with structured diet, exercise, and accountability systems.

Is it safe to stay on Ozempic long-term? Yes. Clinical trials studied semaglutide for up to 2 years with favorable safety profiles. Post-marketing surveillance and real-world data support long-term safety. The cardiovascular outcomes trial (SELECT) showed cardiovascular benefits with long-term use in patients with established cardiovascular disease (Lincoff et al., New England Journal of Medicine 2023).

Will I gain all the weight back if I stop Ozempic? Most patients regain about two-thirds of their lost weight within 12 months of stopping. Complete regain to baseline weight is common by 18 to 24 months. A minority of patients (15 to 20%) maintain significant weight loss through intensive behavioral intervention.

Can you take Ozempic on and off? Intermittent use is not recommended. Weight cycling (repeated loss and regain) may worsen metabolic outcomes. If cost is a concern, maintenance dosing at lower doses is preferable to on-off cycles. Discuss sustainable long-term strategies with your provider.

What is the lowest maintenance dose of Ozempic? No official maintenance dose exists in published guidelines. Real-world experience suggests 0.5 to 1 mg weekly may maintain weight loss in some patients after achieving goal weight on 2.4 mg weekly. Individual response varies. Work with your provider to find your minimum effective dose.

Does stopping Ozempic cause withdrawal symptoms? No. Stopping semaglutide does not cause withdrawal in the medical sense. Appetite returns to baseline or above baseline due to metabolic adaptation, but this is not withdrawal. It is the re-emergence of the underlying disease biology.

How do I stop taking Ozempic without gaining weight? Implement intensive behavioral interventions before discontinuing: daily weight monitoring, structured meal planning, high protein intake (1.2 to 1.6 g/kg), regular resistance training, and weekly accountability check-ins. Consider staged dose reduction rather than abrupt stopping. Set a 5% regain threshold to restart if needed.

Is Ozempic a lifetime medication? For most patients, yes. Obesity is a chronic disease requiring ongoing management. Just as patients with hypertension take blood pressure medication long-term, patients with obesity often require long-term pharmacotherapy. This is appropriate medical management, not dependence.

Can you restart Ozempic after stopping? Yes. Restarting after discontinuation is common and safe. You will typically restart at a low dose (0.25 mg weekly) and retitrate upward, even if you previously tolerated higher doses. The retitration process usually takes 8 to 12 weeks to return to therapeutic doses.

Sources

1. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
2. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
3. Leibel RL et al. Changes in energy expenditure resulting from altered body weight. New England Journal of Medicine. 1995.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
5. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
8. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. International Journal of Obesity. 2013.
9. Wadden TA et al. Effect of intensive behavioral therapy on weight regain after discontinuation of obesity pharmacotherapy. Obesity. 2021.
10. Chao AM et al. Weight maintenance on reduced-dose semaglutide: a retrospective cohort analysis. Obesity Science & Practice. 2023.
11. Wing RR et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2006.
12. Leidy HJ et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition. 2015.
13. Montani JP et al. Weight cycling during growth and beyond as a risk factor for later cardiovascular diseases: the 'repeated overshoot' theory. International Journal of Obesity. 2006.
14. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.